Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 262

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Multicenter Validation of Urinary CXCL9 as a Risk-Stratifying Biomarker for Kidney Transplant Injury

Open access
Hricik, D.E., Nickerson, P., Formica, R.N., Poggio, E.D., Rush, D., Newell, K.A., Goebel, J., Gibson, I.W., Fairchild, R.L., Riggs, M., Spain, K., Ikle, D., Bridges, N.D., Heeger, P.S.·2013·American Journal of Transplantation

Abstract

Noninvasive biomarkers are needed to assess immune risk and ultimately guide therapeutic decision-making following kidney transplantation. A requisite step toward these goals is validation of markers that diagnose and/or predict relevant transplant endpoints. The Clinical Trials in Organ Transplantation-01 protocol is a multicenter observational study of biomarkers in 280 adult and pediatric first kidney transplant recipients. We compared and validated urinary mRNAs and proteins as biomarkers to diagnose biopsy-proven acute rejection (AR) and stratify patients into groups based on risk for developing AR or progressive renal dysfunction. Among markers tested for diagnosing AR, urinary CXCL9 mRNA (odds ratio [OR] 2.77, positive predictive value [PPV] 61.5%, negative predictive value [NPV] 83%) and CXCL9 protein (OR 3.40, PPV 67.6%, NPV 92%) were the most robust. Low urinary CXCL9 protein in 6-month posttransplant urines obtained from stable allograft recipients classified individuals least likely to develop future AR or a decrement in estimated glomerular filtration rate between 6 and 24 months (92.5-99.3% NPV). Our results support using urinary CXCL9 for clinical decision-making following kidney transplantation. In the context of acute dysfunction, low values can rule out infectious/immunological causes of injury. Absent urinary CXCL9 at 6 months posttransplant defines a subgroup at low risk for incipient immune injury.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/ajt.12426

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 262

Metadata

Authors
Hricik, D. E., Nickerson, P., Formica, R. N., Poggio, E. D., Rush, D., Newell, K. A., Goebel, J., Gibson, I. W., Fairchild, R. L., Riggs, M., Spain, K., Ikle, D., Bridges, N. D., & Heeger, P. S.
Venue
American Journal of Transplantation
Publisher
Elsevier BV
Published
2013-10
Volume
13
Issue
10
Pages
2634-2644
ISSN
1600-6135 (ISSN-L)
OpenAlex
W1606523019
Cited by
262
References
29
FWCI
16.44
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multicenter Validation of Urinary CXCL9 as a Risk-Stratifying Biomarker for Kidney Transplant Injury. https://app.cochat.ai/papers/10.1111/ajt.12426
The paper
Hricik, D. E., Nickerson, P., Formica, R. N., Poggio, E. D., Rush, D., Newell, K. A., Goebel, J., Gibson, I. W., Fairchild, R. L., Riggs, M., Spain, K., Ikle, D., Bridges, N. D., & Heeger, P. S. (2013). Multicenter Validation of Urinary CXCL9 as a Risk-Stratifying Biomarker for Kidney Transplant Injury. American Journal of Transplantation. https://doi.org/10.1111/ajt.12426

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.